Search

Your search keyword '"Woong Park, Rae"' showing total 4 results
Start Over Author "Woong Park, Rae"
4 results on '"Woong Park, Rae"'

1. Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study.

Author

Lane, Jennifer CE, Weaver, James, Kostka, Kristin, Duarte-Salles, Talita, Abrahao, Maria Tereza F, Alghoul, Heba, Alser, Osaid, Alshammari, Thamir M, Areia, Carlos, Biedermann, Patricia, Banda, Juan M, Burn, Edward, Casajust, Paula, Fister, Kristina, Hardin, Jill, Hester, Laura, Hripcsak, George, Kaas-Hansen, Benjamin Skov, Khosla, Sajan, Kolovos, Spyros, Lynch, Kristine E, Makadia, Rupa, Mehta, Paras P, Morales, Daniel R, Morgan-Stewart, Henry, Mosseveld, Mees, Newby, Danielle, Nyberg, Fredrik, Ostropolets, Anna, Woong Park, Rae, Prats-Uribe, Albert, Rao, Gowtham A, Reich, Christian, Rijnbeek, Peter, Sena, Anthony G, Shoaibi, Azza, Spotnitz, Matthew, Subbian, Vignesh, Suchard, Marc A, Vizcaya, David, Wen, Haini, Wilde, Marcel de, Xie, Junqing, You, Seng Chan, Zhang, Lin, Lovestone, Simon, Ryan, Patrick, Prieto-Alhambra, Daniel, and OHDSI-COVID-19 consortium

Subjects
OHDSI-COVID-19 consortium, HCQ, depression, epidemiology, RA, psychosis, safety, Arthritis & Rheumatology, Clinical Sciences, Immunology, Public Health and Health Services
Abstract

ObjectivesConcern has been raised in the rheumatology community regarding recent regulatory warnings that HCQ used in the coronavirus disease 2019 pandemic could cause acute psychiatric events. We aimed to study whether there is risk of incident depression, suicidal ideation or psychosis associated with HCQ as used for RA.MethodsWe performed a new-user cohort study using claims and electronic medical records from 10 sources and 3 countries (Germany, UK and USA). RA patients ≥18 years of age and initiating HCQ were compared with those initiating SSZ (active comparator) and followed up in the short (30 days) and long term (on treatment). Study outcomes included depression, suicide/suicidal ideation and hospitalization for psychosis. Propensity score stratification and calibration using negative control outcomes were used to address confounding. Cox models were fitted to estimate database-specific calibrated hazard ratios (HRs), with estimates pooled where I2

Published
2021

4. Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients

Author

Martijn J. Schuemie, Christian G. Reich, Rae Woong Park, Ruijun Chen, David Madigan, Nicole L. Pratt, George Hripcsak, Jon Duke, Sungha Park, Seng Chan You, Marc A. Suchard, Steven Shea, Patrick B. Ryan, Harlan M. Krumholz, Chan You, Seng, Krumholz, Harlan M, Suchard, Marc A, Schuemie, Martijn J, Hripcsak, George, Chen, Ruijun, Shea, Steven, Duke, Jon, Pratt, Nicole, Reich, Christian G, Madigan, David, Ryan, Patrick B, Woong Park, Rae, and Park, Sungha

Subjects
Adult, Male, medicine.medical_specialty, hypertension, Databases, Factual, Scale (ratio), First line, Adrenergic beta-Antagonists, Blood Pressure, 030204 cardiovascular system & hematology, Article, Nebivolol, 03 medical and health sciences, 0302 clinical medicine, β-blocker, Internal Medicine, Humans, Medicine, 030212 general & internal medicine, Stroke, Antihypertensive Agents, business.industry, blood pressure, Middle Aged, antihypertensive agents, Atenolol, medicine.disease, stroke, atenolol, Treatment Outcome, Blood pressure, monotherapy, Hypertension, Emergency medicine, Carvedilol, Female, Observational study, business, medicine.drug
Abstract

Evidence for the effectiveness and safety of the third-generation beta-blockers other than atenolol in hypertension remains scarce. We assessed the effectiveness and safety of beta-blockers as first-line treatment for hypertension using three databases in the United States: two administrative claim databases and one electronic health record-based database from 2001 to 2018. In each database, comparative effectiveness of beta-blockers for the risks of acute myocardial infarction, stroke, and hospitalization for heart failure was assessed, using large-scale propensity adjustment and empirical calibration. Estimates were combined across databases using random-effects meta-analyses. Overall, 118,133 and 267,891 patients initiated third-generation beta-blockers (carvedilol and nebivolol) or atenolol, respectively. The pooled hazard ratios of acute myocardial infarction, stroke, hospitalization for heart failure, and most metabolic complications were not different between the third-generation beta-blockers versus atenolol after propensity score matching and empirical calibration (hazard ratio 1.07, 95% CI 0.74 to 1.55 for acute myocardial infarction; hazard ratio 1.06, 95% CI 0.87 to 1.31 for stroke; hazard ratio 1.46, 95% CI 0.99 to 2.24 for hospitalized heart failure). Third-generation beta-blockers were associated with significantly higher risk of stroke than angiotensin-converting enzyme inhibitors (hazard ratio 1.29, 95% CI 1.03 to 1.72), and thiazide diuretics (hazard ratio 1.56, 95% CI 1.17 to 2.20). In conclusion, this study found many patients with first-line beta-blocker monotherapy for hypertension and no statistically significant differences in the effectiveness and safety comparing atenolol with third-generation beta-blockers. Patients on third-generation beta-blockers had a higher risk of stroke than those on angiotensin-converting enzyme inhibitors and thiazide diuretics.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results